Abstract 1878P
Background
The growing number of patients with genitourinary cancers (GU) could create an increasing burden on GU oncologists. Bureau for Cancer Research (BUCARE) describes the prevalence of burnout in GU oncologists in Central Asia region.
Methods
This is a cross-sectional survey study conducted among practicing cancer care physicians (surgical, medical, radiation) at the ASCO / Asian American GU Symposium ( Almaty, April 2023 ). The primary outcome was burnout experience assessed through the Maslach Burnout Inventory.
Results
A total of 101 oncologists completed the questionnaire. Table summarizes physician's characteristics. Despite the fact that 100% of responders are interested in their work, 66% (67 of 101) had symptoms of burnout (high emotional exhaustion and/or depersonalization scores). Fifty percent of oncologists are ready to turn to a psychologist for help. Significant drivers of burnout identified in multivariable regression modeling included ³20 patients per day (odds ratio [OR] = 14.8; P<0.001) and ³10 working hours per day (OR=8.6; P<0.001). Male gender (OR=0.14; P<0.001) and specialization in radiation therapy (OR=0.20; P<0.01) were associated with lower odds of burnout.
Conclusions
More than half of participants met predefined standardized criteria for burnout. Expanding the staff of GU oncologists and reducing the daily workload may improve the emotional state of physicians. Table: 1878P
Characteristics | N=101 |
Gender, N (%) | |
Female | 68 (67.3) |
Male | 33 (37.7) |
Region, N (%) | |
Kazakhstan | 85 (84.2) |
Other countries | 17 (16.8) |
Specialty, N (%) | |
Surgery | 39 (38.6) |
Medical Oncology | 44 (43.6) |
Radiation Oncology | 18 (17.8) |
Department, N (%) | |
In-patient | 79 (78.2) |
Out-patient | 22 (21.8) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05